PortalPublikationenCyclin D1 is a strong prognostic factor for survival in panc...

Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry

Standard

Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry. / Bachmann, Kai; Neumann, Anna; Hinsch, Andrea; Nentwich, Michael F; El Gammal, Alexander T; Vashist, Yogesh; Perez, Daniel; Bockhorn, Maximilian; Izbicki, Jakob R; Mann, Oliver.

in: J SURG ONCOL, Jahrgang 111, Nr. 3, 01.03.2015, S. 316-23.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bachmann, K, Neumann, A, Hinsch, A, Nentwich, MF, El Gammal, AT, Vashist, Y, Perez, D, Bockhorn, M, Izbicki, JR & Mann, O 2015, 'Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry', J SURG ONCOL, Jg. 111, Nr. 3, S. 316-23. https://doi.org/10.1002/jso.23826

APA

Bachmann, K., Neumann, A., Hinsch, A., Nentwich, M. F., El Gammal, A. T., Vashist, Y., Perez, D., Bockhorn, M., Izbicki, J. R., & Mann, O. (2015). Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry. J SURG ONCOL, 111(3), 316-23. https://doi.org/10.1002/jso.23826

Vancouver

Bachmann K, Neumann A, Hinsch A, Nentwich MF, El Gammal AT, Vashist Y et al. Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry. J SURG ONCOL. 2015 Mär 1;111(3):316-23. https://doi.org/10.1002/jso.23826

Bibtex

@article{0a85f8a2fb8248ab9a2defb403261fd5,
title = "Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry",
abstract = "BACKGROUND AND OBJECTIVE: Cyclin D1 is an important regulator protein for the G1-S cell cycle phase transition. The aim of this trial was to evaluate the impact of the CCND1 polymorphism G870A and corresponding protein expression and CCND1 amplification on the survival of the patients.METHODS: 425 patients with ductal pancreatic adenocarcinoma who underwent resection were included after histopathological confirmation. DNA was analyzed for Cyclin D1 polymorphisms, immunhistochemical examination and fluorescence in situ hybridization analysis of the tumor were performed.RESULTS: Overall, the mean survival was 22.9 months (20.5-25.3). The survival in patients with Cyclin D1 G870A polymorphism Adenine/Adenine was 15.1 months (95% CI 11.3-18.9), 21.5 months (17.4-25.6) for Adenine/Guanine, and 29.4 months (95% CI 23.8-35.0) for Guanine/Guanine (P = 0.003). A shorter survival was associated with strong/moderate protein expression in immunohistochemistry (IHC) compared to weak/no expression (P = 0.028). Additionally, a significant coherency between unfavourable polymorphism (AA/AG) and increased protein expression was detected (P = 0.005).CONCLUSIONS: A strong impact on survival of Cyclin D1 G870A polymorphism and the detected corresponding protein expression was found. The biological mechanism of CCND1 in carcinogenesis has not been fully examined; but at present Cyclin D1 seems to be an interesting biomarker for the prognosis of ductal adenocarcinoma.",
keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Pancreatic Ductal, Cyclin D1, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, In Situ Hybridization, Fluorescence, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Pancreatic Neoplasms, Polymorphism, Genetic, Prognosis, Prospective Studies, Survival Rate, Tumor Markers, Biological",
author = "Kai Bachmann and Anna Neumann and Andrea Hinsch and Nentwich, {Michael F} and {El Gammal}, {Alexander T} and Yogesh Vashist and Daniel Perez and Maximilian Bockhorn and Izbicki, {Jakob R} and Oliver Mann",
note = "{\textcopyright} 2014 Wiley Periodicals, Inc.",
year = "2015",
month = mar,
day = "1",
doi = "10.1002/jso.23826",
language = "English",
volume = "111",
pages = "316--23",
journal = "J SURG ONCOL",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry

AU - Bachmann, Kai

AU - Neumann, Anna

AU - Hinsch, Andrea

AU - Nentwich, Michael F

AU - El Gammal, Alexander T

AU - Vashist, Yogesh

AU - Perez, Daniel

AU - Bockhorn, Maximilian

AU - Izbicki, Jakob R

AU - Mann, Oliver

N1 - © 2014 Wiley Periodicals, Inc.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - BACKGROUND AND OBJECTIVE: Cyclin D1 is an important regulator protein for the G1-S cell cycle phase transition. The aim of this trial was to evaluate the impact of the CCND1 polymorphism G870A and corresponding protein expression and CCND1 amplification on the survival of the patients.METHODS: 425 patients with ductal pancreatic adenocarcinoma who underwent resection were included after histopathological confirmation. DNA was analyzed for Cyclin D1 polymorphisms, immunhistochemical examination and fluorescence in situ hybridization analysis of the tumor were performed.RESULTS: Overall, the mean survival was 22.9 months (20.5-25.3). The survival in patients with Cyclin D1 G870A polymorphism Adenine/Adenine was 15.1 months (95% CI 11.3-18.9), 21.5 months (17.4-25.6) for Adenine/Guanine, and 29.4 months (95% CI 23.8-35.0) for Guanine/Guanine (P = 0.003). A shorter survival was associated with strong/moderate protein expression in immunohistochemistry (IHC) compared to weak/no expression (P = 0.028). Additionally, a significant coherency between unfavourable polymorphism (AA/AG) and increased protein expression was detected (P = 0.005).CONCLUSIONS: A strong impact on survival of Cyclin D1 G870A polymorphism and the detected corresponding protein expression was found. The biological mechanism of CCND1 in carcinogenesis has not been fully examined; but at present Cyclin D1 seems to be an interesting biomarker for the prognosis of ductal adenocarcinoma.

AB - BACKGROUND AND OBJECTIVE: Cyclin D1 is an important regulator protein for the G1-S cell cycle phase transition. The aim of this trial was to evaluate the impact of the CCND1 polymorphism G870A and corresponding protein expression and CCND1 amplification on the survival of the patients.METHODS: 425 patients with ductal pancreatic adenocarcinoma who underwent resection were included after histopathological confirmation. DNA was analyzed for Cyclin D1 polymorphisms, immunhistochemical examination and fluorescence in situ hybridization analysis of the tumor were performed.RESULTS: Overall, the mean survival was 22.9 months (20.5-25.3). The survival in patients with Cyclin D1 G870A polymorphism Adenine/Adenine was 15.1 months (95% CI 11.3-18.9), 21.5 months (17.4-25.6) for Adenine/Guanine, and 29.4 months (95% CI 23.8-35.0) for Guanine/Guanine (P = 0.003). A shorter survival was associated with strong/moderate protein expression in immunohistochemistry (IHC) compared to weak/no expression (P = 0.028). Additionally, a significant coherency between unfavourable polymorphism (AA/AG) and increased protein expression was detected (P = 0.005).CONCLUSIONS: A strong impact on survival of Cyclin D1 G870A polymorphism and the detected corresponding protein expression was found. The biological mechanism of CCND1 in carcinogenesis has not been fully examined; but at present Cyclin D1 seems to be an interesting biomarker for the prognosis of ductal adenocarcinoma.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Pancreatic Ductal

KW - Cyclin D1

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunoenzyme Techniques

KW - In Situ Hybridization, Fluorescence

KW - Lymphatic Metastasis

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Staging

KW - Pancreatic Neoplasms

KW - Polymorphism, Genetic

KW - Prognosis

KW - Prospective Studies

KW - Survival Rate

KW - Tumor Markers, Biological

U2 - 10.1002/jso.23826

DO - 10.1002/jso.23826

M3 - SCORING: Journal article

C2 - 25470788

VL - 111

SP - 316

EP - 323

JO - J SURG ONCOL

JF - J SURG ONCOL

SN - 0022-4790

IS - 3

ER -